☏ +1 650 501 5505 ✉ [email protected]
Drug Pipeline Review Therapy area: Pneumonia40–50 pages · PDF + Excel tracker

Pneumonia Drug Pipeline: 17 Assets by Phase

Pneumonia pipeline: 17 drug candidates in clinical development, 7 in Phase III, from 15 sponsors. Data as of 10 Oct 2026.

Pipeline Terminal Pneumonia Data as of 10 Oct 2026
Candidates in development 17assets Desk-reviewed How this number is madeEvery drug named in an interventional trial, merged across code, generic and brand names, with a live or recent industry trial. Placebo and comparator arms excluded.
Phase III 741% of pipeline Registry How this number is madeCandidates whose highest phase in a live or recent trial is Phase III (Phase II/III counts as Phase II).
Phase II 847% of pipeline Registry
Phase I 212% of pipeline Registry
Sponsors 15top 5 hold 41% Registry How this number is madeCompanies credited with at least one candidate: the lead sponsor on most of that candidate's industry trials.
Registered trials 16070 running Registry How this number is madeInterventional trials on ClinicalTrials.gov for the conditions in scope, updated since 3 Oct 2021.
Readouts in 12 months 6Phase II or later Sponsor dates How this number is madeCandidates with a registered primary completion date in the next 12 months. Dates are the sponsor's own and often move.
Trials with US sites 2717% · Europe 36% Registry How this number is madeTrials with at least one site in the United States; Europe is the EU/EEA, the UK and Switzerland. A trial counts in every region where it has a site.

Candidates by highest phase reached

Phase I2
Phase II8
Phase III7

Next registered primary completions, Phase II or later

CandidatePhasePrimary completion
PralurbactamPhase IIIDec 2026 (est.)
OMN6Phase IIMar 2027 (est.)
TQD3524Phase IIJul 2027 (est.)

Candidates in development by lead sponsor

BioVersys AG2
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.2
Aptarion Biotech AG1
Jiangsu Aosaikang Pharmaceutical Co., Ltd.1
Eagle Pharmaceuticals, Inc.1

Phase II and III primary completions per quarter

Q4 20261
Q1 20271
Q2 20270
Q3 20272
Q4 20273
Q1 20280
Q2 20281
Q3 20281

Answers at a glance

  • 7 of 17 pneumonia candidates (41%) are in Phase III.
  • BioVersys AG runs the largest pneumonia pipeline, with 2 candidates.
  • 6 readouts are due in 12 months; the next is Pralurbactam in Dec 2026.
  • 35 trials are recruiting patients now; 17% of all trials have a US site and 36% a European one.
17 candidates160 trials64 countriesData as of 10 Oct 2026Next refresh by 8 Jan 2027
USD 3,000Pipeline Snapshot Download Free Sample Request the Review
Edition: data as of 10 Oct 2026 Next refresh: by 8 Jan 2027 Change: First edition

Request a free sample

A sample of the Pneumonia Pipeline Review: the full chapter list, the tracker columns and two asset profiles from the report. The Research Desk reviews your request and emails it, usually within one business day.

Pneumonia has 17 drug candidates in active clinical development, of which 7 are in Phase III, 8 in Phase II and 2 in Phase I, according to Douglas Insights' count of 160 interventional trials registered on ClinicalTrials.gov (data as of 10 Oct 2026).

The pneumonia drug pipeline is the set of medicines that sponsors are still testing in people for this condition: each candidate is counted once, at the highest phase it has reached in a running or recently completed trial. Medicines already on the market and studied only in Phase IV trials are kept out of the count.

How many pneumonia drugs are in each phase of development?

Douglas Insights counts 7 pneumonia candidates in Phase III, 41% of the 17 assets in development; Phase II holds 8 and Phase I holds 2.

Phase I2Phase II8Phase III7
Candidates by highest phase reached. Source: Douglas Insights from ClinicalTrials.gov, data as of 10 Oct 2026.
Phase (highest reached)AssetsShare of pipeline
Phase III741%
Phase II847%
Phase I212%
Total17100%

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each pneumonia asset appears in exactly one row. The 70 trials still recruiting or running carry 44% of the 160 registered trials in scope.

Which approved pneumonia medicines are still in trials?

2 medicines already on the market are still being tested in pneumonia Phase IV trials; Meropenem has the most, with 8 registered trials.

MedicineLead sponsorRegistered trials
MeropenemSeveral sponsors8
Ceftazidime-avibactamSeveral sponsors5

Post-approval pneumonia trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many pneumonia trials are recruiting patients now?

35 pneumonia trials are recruiting patients and 28 more have not started recruiting yet, out of 160 interventional trials in scope; together they make up 39% of the trial base.

Registry statusTrialsShare
Completed6440%
Recruiting3522%
Not yet recruiting2818%
Status not verified138.1%
Terminated85.0%
Withdrawn53.1%
Active, not recruiting42.5%
Enrolling by invitation31.9%

Terminated, suspended and withdrawn pneumonia trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the pneumonia pipeline?

BioVersys AG leads the pneumonia pipeline with 2 candidates; the top 5 sponsors hold 41% of the 17 assets, and 15 sponsors run at least one.

SponsorAssets in developmentShare
BioVersys AG212%
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.212%
Aptarion Biotech AG15.9%
Jiangsu Aosaikang Pharmaceutical Co., Ltd.15.9%
Eagle Pharmaceuticals, Inc.15.9%

Industry sponsors lead 51 of the 160 pneumonia trials (32%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the pneumonia pipeline?

Mechanism and drug-type classification for the 17 pneumonia candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What pneumonia trial readouts are coming next?

6 pneumonia candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

CandidateSponsorPhasePrimary completionRegistry
PralurbactamQilu Pharmaceutical Co., Ltd.Phase IIIDec 2026 (estimated)NCT07089186
OMN6Omnix Medical LtdPhase IIMar 2027 (estimated)NCT06087536
TQD3524Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase IIJul 2027 (estimated)NCT07512596

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many pneumonia readouts fall in each quarter?

9 pneumonia candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 3, due in Q4 2027.

QuarterPhase III readoutsPhase II readoutsTotal
Q4 2026101
Q1 2027011
Q2 2027000
Q3 2027022
Q4 2027123
Q1 2028000
Q2 2028101
Q3 2028101

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most pneumonia trials?

France hosts the most pneumonia trials, with sites in 32 of the 160 studies (20%); trials in scope run in 64 countries in all.

CountryTrials with a siteShare of trials
France3220%
United States2717%
China2415%
Spain1912%
Greece159.4%
Russia148.8%
Egypt127.5%
Taiwan106.3%

A multinational pneumonia trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are pneumonia drugs being tested?

27 of the 160 pneumonia trials (17%) have a site in the United States, 57 (36%) in Europe and 24 (15%) in China; 5 of the 17 candidates in development are tested in the US.

RegionTrials with a siteShare of trialsCandidates testedRegulator
United States2717%5FDA
Europe (EU/EEA, UK, Switzerland)5736%7EMA, MHRA, Swissmedic
China2415%8NMPA
Japan21.3%1PMDA
Rest of world6943%7national regulators

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational pneumonia trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the pneumonia pipeline since the last update?

This is the first edition of the pneumonia pipeline count, dated 10 Oct 2026. The next refresh is due by 8 Jan 2027, and each refresh lists the assets that entered, advanced or dropped out.

How does Douglas Insights count the pneumonia pipeline?

Douglas Insights read 160 interventional trials registered on ClinicalTrials.gov for the conditions "Community-Acquired Pneumonia", "Bacterial Pneumonia", "Hospital-Acquired Pneumonia", "Ventilator-Associated Pneumonia" (excluding "COVID-19") and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 17 unique candidates.

  1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
  2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
  3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
  4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

What does the Pneumonia Pipeline Review include?

The Pneumonia Pipeline Review covers all 17 candidates in an Excel tracker and profiles the leading 17 in a 40–50 page report, ending with the research desk's ranked view of the candidates most likely to win.

11 chapters40–50 pages25 asset profilesExcel tracker of all 17 candidates
01Executive summary and our call2–3 pp

The pipeline on one page and the desk's verdict on where pneumonia treatment is heading.

  • Pipeline size and phase mix
  • The three calls that matter
  • What changed since the last edition
02Disease and unmet need3 pp

Who is treated today, what current therapy leaves unmet, and how regulators judge new medicines.

  • Patient population and diagnosis
  • Treatment guidelines and gaps
  • Regulatory endpoints
03Approved therapies3 pp

The marketed medicines every pneumonia candidate will be measured against.

  • Marketed medicines and their sponsors
  • Post-approval trials
  • The bar a new entrant must clear
04Pipeline at a glance4 pp

Every candidate counted by phase, drug type, sponsor and country.

  • Assets by phase and drug type
  • Sponsors by size of pipeline
  • Trial footprint: US, Europe, China, Japan
05Mechanism landscape and white space5 pp

Which mechanisms are crowded and which no sponsor has entered.

  • Mechanism classes and crowding
  • Classes with no candidate yet
  • Differentiation by route and dosing
06Key asset profiles12–15 pp

The leading 25 candidates, one profile each, every claim linked to a source document.

  • Design and endpoints of the pivotal trials
  • Data to date, with sources
  • Next readout and the risk to it
07Catalyst calendar3 pp

Readouts, filings and regulatory decisions 24 months ahead.

  • Readouts by quarter
  • Filings and regulatory decisions
  • Date confidence for each event
08Deals and partnering3 pp

Who is licensing, buying and partnering in pneumonia, and on what terms.

  • Licensing and M&A in the area
  • Deal terms where disclosed
  • Sponsors open to partnering
09Sponsor landscape3 pp

Large pharma against biotech, and how concentrated the pipeline is.

  • Pipeline share by sponsor
  • Sponsor-by-phase matrix
  • New entrants since the last edition
10Our call: winners, risks, opportunities3–4 pp

The candidates most likely to win, ranked, with the reasoning and evidence.

  • Ranked candidates
  • Risks that could change the order
  • Openings for new entrants and investors
11Methodology and source log2 pp

How the count is built and every document behind it.

  • How candidates are counted and merged
  • Every source document listed
  • The ten quality checks

Ways to buy the Pneumonia review

OptionWhat you getDeliveryPrice
Pipeline SnapshotThis therapy area as published: PDF report + Excel trackerReady nowUSD 3,000Enquire
Pipeline ReviewYour indication, geography and phase cut-off; ranked calls and an analyst call2–3 weeksFrom USD 4,000Enquire
Company AssessmentOne sponsor's full pipeline against its peers2 weeksFrom USD 5,000Enquire

Email me the sample and chapter listAsk for a quote

Frequently asked questions about the pneumonia pipeline

How many drugs are in the pneumonia pipeline?

17 drug candidates are in active clinical development for pneumonia, with 7 in Phase III, per Douglas Insights (data as of 10 Oct 2026).

Which company has the most pneumonia drugs in development?

2 candidates make BioVersys AG the largest pneumonia pipeline sponsor, out of 15 sponsors counted by Douglas Insights.

When is the next pneumonia trial readout?

Dec 2026 is the registered primary completion of the Phase III trial of Pralurbactam (NCT07089186), the next pneumonia catalyst in Douglas Insights' calendar.

How many pneumonia trials run in the United States and Europe?

27 pneumonia trials have a US site and 57 a European site, out of 160 registered trials counted by Douglas Insights (data as of 10 Oct 2026).

How often is the pneumonia pipeline count updated?

90 days is the refresh cycle; this edition uses registry data as of 10 Oct 2026 and the next is due by 8 Jan 2027.

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Cite this page Douglas Insights (2026). Pneumonia Drug Pipeline, data as of 10 Oct 2026. https://www.douglasinsights.com/pipeline/pneumonia/